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cryoablation of metastatic lung tumors 
in patients-safety and efﬁcacy: the 
ECLIPSE trial-interim analysis at 
1-year”1 has shown that this technique is 
moderately efﬁcacious in terms of local 
control of disease. But like so many sim-
ilar reports of techniques for removal 
or ablation of pulmonary metastases, it 
is based on the uncertain premise that 
removing a few asymptomatic “oligo-
metastases” improves patients’ survival.
The oligometastatic state is 
poorly deﬁned and has no demon-
strable basis in cancer biology or bio-
statistics.2 The term was ﬁrst coined 
in 1995 but citations only began to 
increase in the 2000s. Writing in 2014 
an interdisciplinary group of authors, 
including Weichselbaum, one of the 
originators of the term, suggested that 
there might be more wishful think-
ing than evidence.3 Although de Baere 
et al.1 believe that metastasectomy is 
“the standard of care,” the only evi-
dence they cite is a registry of surgeons’ 
self-reported results from the 1945 to 
1995. The recent literature on surgical 
metastasectomy is considerably more 
circumspect.4 There are no known 
randomized trials or other controlled 
studies to prove effectiveness. This is 
the reason for running the Pulmonary 
Metastasectomy in Colorectal Cancer 
(PulMiCC) randomized controlled trial 
now open internationally.
The practice of lung metastasec-
tomy is very highly selective and targets 
those with one or very few metastases 
and longer intervals between primary 
resection and lung metastasectomy. 
These are inherently the longest living 
patients at the tail end of the survival 
distribution of metastatic cancer. Some 
are alive for 5 years with or without 
treatment. These patients, destined to 
survive without metastasectomy, are 
greatly over represented in the groups 
selected for surgery creating the illu-
sion of effectiveness.5 In ECLIPSE, 
75% of the patients had had a variety of 
prior treatments for metastases. By 12 
months, 40% had developed new metas-
tases, with a mean time to developing 
them of 10.7 months, but none had 
died of cancer. This suggests that these 
patients had widespread but slow grow-
ing subclinical metastatic disease and 
raises questions about the justiﬁcation 
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tumor descriptors of the tumor, node and 
metastasis (TNM) classiﬁcation of lung 
cancer.2 As the authors explained, before 
the 7th edition of the TNM classiﬁcation, 
there was no speciﬁc code to describe 
lymphangitic carcinomatosis in the lung, 
which is mainly a situation found at clin-
ical staging. To help register cases in a 
uniform way, the code cLy was proposed 
for prospective testing. This code is an 
optional descriptor that is not integrated 
in the T or the M components of the clas-
siﬁcation. Therefore, it has to be regis-
tered separately and added to the regular 
TNM. For example, a right upper lobe 
tumor invading the chest wall presenting 
with radiological signs of lymphangitis 
in the upper and middle lobes, but with-
out nodal disease or distant metastasis, 
would be classiﬁed as cT3N0M0 cLy3.
In the International Association 
for the Study of Lung Cancer (IASLC) 
database,3 data on the cLy descriptor are 
scarce. This descriptor is available for 
patients registered prospectively through 
the electronic data capture system, only, 
and not for those registered retrospec-
tively. In total, there were 69 patients with 
non–small-cell lung cancer (NSCLC) 
with some degree of lymphangitis: 
cLy1 33 (48%), cLy2 9 (13%), cLy3 14 
(20%), and cLy4 13 (19%). Ten additional 
patients with small-cell lung cancer also 
presented with lymphangitis. Among 
patients with NSCLC, lymphangitis was 
more frequent in larger tumors (29 cT2, 
9 cT3, and 27 cT4) than in earlier ones 
(3 cT1 and 1 cTX). The survival analy-
sis of these patients does not clarify the 
prognostic impact of this descriptor as 
the estimated 1-year survival is approxi-
mately 41% for patients with cLy1, cLy2, 
and cLy4, with a paradoxically high 61% 
estimated 1-year survival for patients 
with cLy3. So, with these data, solid con-
clusions cannot be drawn. We certainly 
need this information on a larger number 
of patients to fully assess the prognostic 
relevance of the anatomical extent of lym-
phangitis. The IASLC database used for 
the revision of the 7th edition of the TNM 
classiﬁcation is predominantly surgical, 
with 85% of registered patients having 
been treated surgically, either with sur-
gery alone or in combination with chemo-
therapy and radiotherapy. This explains 
why there are so few patients with lung 
cancer and associated lymphangitis.
We thank Drs. Singh, Baldi, and 
Behera for their interest in the IASLC 
Lung Cancer Staging Project and for hav-
ing pointed out the prognostic implica-
tions of lymphangitis. Only with larger 
and more detailed databases, we will be 
able to further reﬁne and better under-
stand its prognostic impact.
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To the Editor:
The report of 1-year results from 
the nonrandomized study “Evaluating 
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- cancelation of any chance of cure 
in the active surveillance arm, 
even if such cure is limited with 
13.1 ± 1.7% patients free of dis-
ease at 4 years after radiofrequency 
ablation (RFA) in our series of 566 
patients with 1037 lung metastases.3
Concerning the “moderate efﬁ-
cacy” of cryoablation describe by 
Dr. Macbeth, we report 1-year efﬁcacy of 
94.2% with cryoablation1 and 89% at 4 
years with RFA,3 which is in the range to 
what usually reported after surgical resec-
tion.4 Concerning safety of cryoablation, 
no major side effects were recorded, and 
most common side effect was pneumo-
thorax requiring small bore chest tube 
placement in 18.8% of patients with tube 
retrieval at day 1 or 2 after treatment.1 
This compares favorably with surgery 
requiring large bore chest tube insertion 
in all patients with later retrieval.
Trying to answer the question of 
Dr. Treasure, “Is cryoablation of lung 
metastases a justiﬁable procedure?,” 
the ﬁrst answer is that we are convinced 
that minimal-invasive ablation tech-
niques including cryotherapy or RFA 
are more justiﬁable than surgery due to 
their high efﬁcacy and low morbidity, 
thus avoiding “the inevitable downside 
of pain of thoracotomy and, with larger 
resections, loss of lung function” as 
describe elsewhere by Dr. Treasure.2 
Then, even in a randomized trial as 
suggested by Dr. Macbeth, it might 
be difﬁcult to “see the signal from the 
noise with the inevitable use of combi-
nations of therapies making it impos-
sible to discern the effect of surgery on 
survival” as explain by Dr. Treasure.2 
Percutaneous ablation might provide 
the gain of complete control of the 
disease and avoid the inevitable down-
side of surgery and replace surgery 
for small size metastases in a selected 
population. We do think that cryoabla-
tion of lung metastases is a justiﬁable 
procedure when trying to approach 
individual patients care when there is 
lack of level I evidence.
Thierry de Baere, MD
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for trying to ablate a few radiologically 
detectable pulmonary metastases.
Although there is insufﬁcient evi-
dence that removing lung metastases 
by any modality improves survival, is it 
good palliation? Patients selected for sur-
gical metastasectomy have almost always 
been asymptomatic. It is unusual for lung 
metastases to contribute to symptoms 
near the end of life or to contribute to 
the mode of death. This study shows that 
cryotherapy is not a harmless treatment. 
One in ﬁve patients had a postprocedural 
pneumothorax. The information in this 
small series of patients is insufﬁcient to 
assess other complications, but it is likely 
that they will suffer some of the effects of 
cavitating lung disease including infec-
tion and hemoptysis.
On the available evidence, removal 
or ablation of asymptomatic lung metas-
tases by any modality cannot be justiﬁed 
for survival or palliation. The oncologi-
cal community should not accept it as 
“standard” but should collaborate in ran-
domized trials to assess its effectiveness.
Fergus Macbeth, DM, FRCR, FRCP
Wales Cancer Trials Unit
Cardiff, United Kingdom 
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In reply:
We thank Dr. Macbeth and his 
coworkers for the interest they placed 
in reading our publication in Journal of 
Thoracic Oncology1 and greatly appre-
ciated their comments. We do agree 
that there is no level I evidence of ben-
eﬁt of lung metastasectomy for overall 
survival, although many large series 
suggest that a beneﬁt might exist. A 
randomized control trial as Pulmonary 
Metastasectomy in Colorectal Cancer2 
is an interesting way to try to answer the 
question of beneﬁt in terms of overall 
survival, but the randomization between 
lung metastasectomy and active surveil-
lance in the PULMICC study has limi-
tations such as the following:
- recruitment, because it is difﬁcult 
for a patient accessible to surgery 
that the choice in between surgery 
and no treatment will be made 
after “flipping a coin,” and this is 
probably one of the reason why 
PULMICC study is recruiting 
slowly.
- deﬁnition of what is active surveil-
lance and when to treat a patient 
under active surveillance? Is it pos-
sible/ethical to refuse surgery in the 
active surveillance arm? What about 
a single lung metastasis that grows 
from 1.5 to 3.5 cm in 18 months, 
remains single location of disease 
and is now abutting the pleura? Will 
we be really able to measure the 
beneﬁt of active surveillance when 
crossover is unavoidable?
- difﬁculty in measuring possible ben-
eﬁt of resection or ablation to the 
patient beside overall survival. What 
is the beneﬁt of being disease free for 
a mean of 10 months after ablation?
DOI: 10.1097/JTO.0000000000000695
Copyright © 2015 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/15/1012-e121
